SIRT2 and gastric cancer: Furthermore, sirReal2 can suppress the deacetylation activity of SIRT2 and its downstream target PEPCK1, as well as mitochondrial metabolism and the RAS/ERK/JNK/MMP-9 pathway, limiting migration and invasion in GC cells.